| Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. Co.'s lead clinical candidate, APVO436 is an ADAPTIR bispecific immunotherapeutic protein targeting CD123, a cell surface receptor highly expressed on several hematological malignancies and CD3, a component of the T-cell receptor. ALG.APV-527 is an investigational bispecific ADAPTIR candidate, partnered with Alligator Bioscience AB, featuring a mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen overexpressed in a number of different types of cancer. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate. We show 23 historical shares outstanding datapoints in our coverage of APVO's shares outstanding history.|
Understanding the changing numbers of APVO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APVO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APVO by allowing them to research APVO shares outstanding history
as well as any other stock in our coverage universe.